Tg Therapeutics (TGTX) Non-Current Assets (2010 - 2026)

Tg Therapeutics' Non-Current Assets history runs 17 years deep, the most recent figure standing at $441.9 million for Q1 2026.

• On a quarterly basis, Non-Current Assets rose 3528.11% year-over-year to $441.9 million in Q1 2026; TTM through Mar 2026 was $1.3 billion, a 2716.69% increase from a year earlier, with the FY2025 full-year figure at $432.5 million, up 3716.87% from the prior year.
• Non-Current Assets improved to $441.9 million in Q1 2026 per TGTX's latest filing, from $432.5 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $441.9 million in Q1 2026 and bottomed at $11.3 million in Q4 2024.
• The 5-year median for Non-Current Assets is $12.7 million (2024), against an average of $95.1 million.
• Across the five-year window, Non-Current Assets tumbled 79.32% in 2023 and jumped 3716.87% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $25.3 million in 2022, then plunged by 53.97% to $11.6 million in 2023, then slipped by 2.69% to $11.3 million in 2024, then soared by 3716.87% to $432.5 million in 2025, then advanced by 2.17% to $441.9 million in 2026.
• Per Business Quant, the three latest TGTX Non-Current Assets figures stand at $441.9 million (Q1 2026), $432.5 million (Q4 2025), and $425.3 million (Q3 2025).